Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XC001 endocardial gene therapy for refractory angina due to obstructive coronary artery disease
NL-OMON58108Recruiting
- Sponsor
- XyloCor Therapeutics
- Start
- May 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Randomised, double-blind trial of encoberminogene rezmadenovec in angina pectoris and coronary arteriosclerosis (2 arms), sponsored by XyloCor Therapeutics. Primary endpoint: Composite therapy response at Weeks 12 and 26. Started May 2026; status: recruiting.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
angina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON58108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58108.